Clinical Trial Sites

We are currently engaged in or have completed clinical trials in cooperation with the following medical centers:

Spinal Cord Injury

Balgrist University Hospital, University of Zurich
StemCells is conducting a Phase I/II clinical trial of HuCNS-SC cells in Switzerland at the Balgrist University Hospital, University of Zurich, one of the leading medical centers in the world for spinal cord injury and rehabilitation.   The principal investigator is Armin Curt, MD, Professor and Chairman, Spinal Cord Injury Center at the University of Zurich, and Medical Director of the Paraplegic Center at the Balgrist University Hospital.   Dr. Curt is an internationally renowned medical expert in spinal cord injury.  The trial was initiated in March 2011, and is currently open for enrollment.


Retina Foundation of the Southwest, Dallas Texas
StemCells is conducting a Phase I/II clinical trial of HuCNS-SC cells in the dry form of age-related macular degeneration (AMD) at the Retina Foundation of the Southwest RFSW) in collaboration with Principal Investigator David G. Birch, Ph.D., Chief Scientific and Executive Officer of the RFSW.  The trial was initiated in June 2012 and is currently open for enrollment.

Patient Enrollment

Spinal Cord Injury Trial –

For enrollment inquiries, please contact the trial site
in Switzerland at
+41 44 386 59 70 or at

Dry AMD Trial –

For enrollment Inquiries please contact the trial site in Dallas, Tx at +1 (214)363-3911 ext. 114 or at

Please Note!

You are about to open a web page or document that is hosted by a third party and is not maintained by StemCells, Inc. and to which our Privacy Policy does not apply.

This link is provided to you for convenience and does not serve as an endorsement by StemCells, Inc. of any information or contacts that you may find on this third party site.

Cancel | Continue